Visão geral da empresa
A biopharmaceutical entity focused on developing transformative medicines based on messenger ribonucleic acid (mRNA), CureVac N.V. operates within the healthcare sector, specifically the biotechnology industry, where the development of novel therapeutic platforms is central to the business model. As of December 18, 2025, the company's corporate structure changed significantly as it was acquired by BioNTech SE, marking a pivotal shift in its operational status and ownership. The company maintains a substantial market capitalization of $1.05B and employs a workforce of 825 individuals dedicated to research and development. Despite the recent acquisition, the financial reporting reflects a revenue base of $70.74M over the trailing twelve months, indicating that the entity continues to generate cash flows even as its strategic direction evolves under new ownership. These valuation metrics suggest the market still assigns a significant enterprise value to the acquired asset, reflecting the underlying technology's potential and the scale of operations required to advance clinical and preclinical candidates for various diseases.
Saúde financeira
The company reported a revenue of $70.74M for the trailing twelve months, while achieving a net income of $128.82M and an EBITDA of $193.69M, creating a notable divergence between top-line revenue and bottom-line profitability. The substantial gap between revenue and net income reveals a highly leveraged cost structure where non-operating income or specific accounting adjustments significantly boosted the net income figure relative to the revenue generated from core operations. Although free cash flow data is not currently disclosed as N/A, the company holds a robust cash reserve of $416.09M, which provides a significant buffer for funding research activities or managing obligations during the transition period following the acquisition. The company's profitability is further highlighted by a gross margin of 93.3%, an operating margin of 573.0%, and a profit margin of 182.1%, all of which indicate an exceptionally efficient cost structure relative to sales and significant non-operating gains or income sources. In terms of leverage, the company holds $416.09M in cash against $35.07M in debt, resulting in a debt-to-equity ratio of 4.03, which suggests a balance sheet that appears highly leveraged based on the equity ratio despite the presence of substantial liquid assets. The current ratio stands at 3.70, indicating that the company possesses more than three times the liquid assets necessary to cover its short-term liabilities, which points to strong short-term liquidity. Furthermore, the Return on Equity and Return on Assets are listed as N/A, which limits the ability to assess management effectiveness through traditional return metrics, likely due to the recent acquisition accounting or the specific capitalization structure of the company at this juncture.
Avaliação de valorização
Valuation metrics for CureVac N.V. present a complex picture with a trailing P/E ratio of 6.96 contrasted sharply against a forward P/E of -8.02, implying that expected future earnings are currently projected to be negative or that the forward metric is heavily influenced by anticipated losses or acquisition-related accounting adjustments. The price-to-book ratio is recorded at 0.83, indicating that the stock trades at a discount to its book value, which may reflect market skepticism regarding future profitability or the impact of the recent acquisition on asset valuations. Alternative valuation measures such as the price-to-sales ratio of 14.83 and an EV/EBITDA of 2.39 provide context, suggesting that the company is valued high relative to its sales but low relative to its earnings power, a common dynamic in biotechnology firms with high growth potential or significant non-recurring income. The stock's trading range over the past year spans a 52-week high of $5.72 and a 52-week low of $2.48, placing the current valuation within a wide band that reflects significant market volatility and uncertainty surrounding the asset's future trajectory. The beta value of 1.84 indicates that the stock exhibits high price volatility relative to the broader market, moving with greater intensity than the general index, which is characteristic of small-cap biotechnology companies sensitive to clinical trial outcomes and regulatory developments.
Growth & Income
The company's financial trajectory shows a revenue growth rate of -89.0% year-over-year, while earnings growth remains positive at 24.0%, implying that profitability is being driven by factors other than top-line expansion, such as non-operating income or cost reductions, rather than organic business growth. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that any generated earnings are retained within the company to fund ongoing research and development rather than being distributed to shareholders. The disparity between declining revenue and rising earnings highlights a unique financial phase where the company's profitability is decoupled from its sales volume, a situation often seen during periods of significant restructuring or post-acquisition integration. Overall, the growth and income profile for CureVac N.V. is characterized by high volatility and a reliance on non-operating income streams rather than sustained organic growth or dividend distributions, reflecting the specific challenges and opportunities inherent in the biotechnology sector following a major acquisition.